Between Robert F. Kennedy Jr. and Vivek Ramaswamy, the incoming Trump administration has highly divergent views on regulating the pharmaceutical industry. Why it matters: Both say there are deep problems with America's drug development system. But RFK Jr., the HHS secretary designee, is calling for more oversight of drugs and vaccines and diminished federal funding for R&D. - Ramaswamy, a biotech entrepreneur who will lead a new "Department of Government Efficiency" with Elon Musk, is a small government aficionado who's called for fewer barriers to bringing drugs to market.
Their differences add another layer of uncertainty for pharmaceutical companies trying to navigate what could be dizzying changes in the new administration. Where it stands: Kennedy's priorities include a crackdown on direct-to-consumer drug ads and diverting half of the National Institutes of Health's research budget from infectious diseases to alternative cures and preventive health. - The vaccine critic wants to see more safety data on shots already on the market. And before Trump selected him for the top health care post, Kennedy also pledged to end the FDA's "war" on "anything that can't be patented by Pharma."
Ramaswamy wrote on social media last week that his biggest problem with the FDA is the agency's layers of bureaucracy, which he said stifle innovation. - "This stops patients from accessing promising therapies & raises prescription drug costs by impeding competition. The agency's staff have callous disregard for the impact of their daily decisions on the cost of developing new therapies, which inevitably gets passed on to the healthcare system," Ramaswamy posted on X.
Yes, but: Ramaswamy and Kennedy are aligned on some issues. Both have said they want to root out corruption in the FDA. They've also both advocated for restructuring federal departments and firing career civil service employees. More here
|